IPD Share Price Performance
Recent IPD News & Updates
No updates
ImpediMed Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.01
- Gross Margin
- 87.88%
- Net Profit Margin
- -183.82%
- Debt/Equity Ratio
- 0%
ImpediMed Limited Competitors
About IPD
- Founded
- 1999
- Employees
- 83
- CEO
- WebsiteView website
ImpediMed Limited, a medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema and deliver snapshot of fluid status and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-car body composition analysis; and HF-Dex analysis for point-or care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company was incorporated in 1999 and is headquartered in Carlsbad, California with additional office in Lindfield, Australia.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.1%
- 1 Year: 17.7%
- Year to Date: 5.9%
The market has dropped by 18% in the last 7 days, with the Financials sector leading declines. In the last year, the market is actually up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading